INmune Bio Statistics

Total Valuation

INmune Bio has a market cap or net worth of $185.92 million. The enterprise value is $164.84 million.

Market Cap	185.92M
Enterprise Value	164.84M

Important Dates

The next estimated earnings date is Thursday, July 31, 2025, after market close.

Earnings Date	Jul 31, 2025
Ex-Dividend Date	n/a

Share Statistics

INmune Bio has 23.21 million shares outstanding. The number of shares has increased by 17.00% in one year.

Current Share Class	23.21M
Shares Outstanding	23.21M
Shares Change (YoY)	+17.00%
Shares Change (QoQ)	+1.12%
Owned by Insiders (%)	19.48%
Owned by Institutions (%)	25.91%
Float	15.21M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3,676.52
Forward PS	n/a
PB Ratio	5.95
P/TBV Ratio	13.97
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	3,296.72
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.64, with a Debt / Equity ratio of 0.01.

Current Ratio	2.64
Quick Ratio	2.62
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-96.12

Financial Efficiency

Return on equity (ROE) is -139.01% and return on invested capital (ROIC) is -77.49%.

Return on Equity (ROE)	-139.01%
Return on Assets (ROA)	-61.33%
Return on Invested Capital (ROIC)	-77.49%
Return on Capital Employed (ROCE)	-138.99%
Revenue Per Employee	$2,273
Profits Per Employee	-$1.85M
Employee Count	22
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -5.65% in the last 52 weeks. The beta is 1.57, so INmune Bio's price volatility has been higher than the market average.

Beta (5Y)	1.57
52-Week Price Change	-5.65%
50-Day Moving Average	7.54
200-Day Moving Average	6.71
Relative Strength Index (RSI)	56.51
Average Volume (20 Days)	487,781

Short Selling Information

The latest short interest is 6.18 million, so 26.62% of the outstanding shares have been sold short.

Short Interest	6.18M
Short Previous Month	5.87M
Short % of Shares Out	26.62%
Short % of Float	40.62%
Short Ratio (days to cover)	23.31

Income Statement

In the last 12 months, INmune Bio had revenue of $50,000 and -$40.80 million in losses. Loss per share was -$1.94.

Revenue	50,000
Gross Profit	50,000
Operating Income	-41.52M
Pretax Income	-37.74M
Net Income	-40.80M
EBITDA	n/a
EBIT	-41.52M
Loss Per Share	-$1.94

Full Income Statement

Balance Sheet

The company has $19.34 million in cash and $347,000 in debt, giving a net cash position of $18.99 million or $0.82 per share.

Cash & Cash Equivalents	19.34M
Total Debt	347,000
Net Cash	18.99M
Net Cash Per Share	$0.82
Equity (Book Value)	29.67M
Book Value Per Share	1.29
Working Capital	13.03M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-32.71M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-83,046.00%
Pretax Margin	-81,592.00%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

INmune Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-17.00%
Shareholder Yield	-17.00%
Earnings Yield	-22.19%
FCF Yield	n/a

Analyst Forecast

The average price target for INmune Bio is $24.33, which is 203.75% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$24.33
Price Target Difference	203.75%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	537.27%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

INmune Bio has an Altman Z-Score of 1.89 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.89
Piotroski F-Score	2